Complex pharmacotherapy is common in patients with bipolar disorder. This study examined the prevalence of such complex regimens in bipolar disorder patients and sought to characterize factors that influence polypharmacy prescribing patterns.
Ketamine has emerged as a promising treatment for patients with bipolar depression, particularly those with acute suicidality, Here, the authors report a case of a patient who received ketamine infusions, resulting in induction of a manic episode.
Are women with vaginismus more susceptible to developing bipolar disorder? This study investigated the affective temperaments of women with vaginismus compared to healthy controls. The results may surprise you.
The question of whether, and when, antidepressants are appropriate in bipolar disorder is a hotly debated topic. This ASCP Corner article summarizes the key concepts with greatest relevance for clinical decision-making.
Despite substantial research on sex differences in adults with bipolar disorder, little is known about this topic in youth. This prospective study examined sex differences in mood symptomatology and psychiatric comorbidity in youth with bipolar disorder.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”